Irciniastatin analogues

Patent metadata

Field	Value
Publication number	US-9540355-B2
Application number	US-201414761030-A
Country	US
Kind code	B2
Filing date	Jan 15, 2014
Priority date	Jan 15, 2013
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

The present invention is directed to irciniastatin analogs. Uses of these analogs also described.

First claim

What is claimed:

1. A compound of Formula I, or a stereoisomer thereof,

wherein
R 1 is hydrogen; and
R 2 is halogen, O—C(O)phenyl, O—C(O)C 1-6 alkyl, or C 1-6 alkyl, or wherein R 1 and R 2 together form ═CR 3 R 4 or ═NR 5 wherein R 3 and R 4 are independently hydrogen or C 1-6 alkyl, and R 5 is O—C 1-6 alkyl;
or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is halogen.

3. The compound of claim 2 , or a stereoisomer thereof, wherein R 2 is F.

4. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is —OC(O)phenyl.

5. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is —OC(O)C 1-6 alkyl.

6. The compound of claim 5 , or a stereoisomer thereof, wherein R 2 is
—OC(O)CH 3 .

7. The compound of claim 1 , or a stereoisomer thereof, wherein R 2 is
—C 1-6 alkyl.

8. The compound of claim 1 , or a stereoisomer thereof, wherein R 1 and R 2 together are ═CR 3 R 4 .

9. The compound of claim 8 , or a stereoisomer thereof, wherein R 3 and R 4 are each hydrogen.

10. The compound of claim 8 , or a stereoisomer thereof, wherein R 3 and R 4 are each C 1-6 alkyl.

11. The compound of claim 8 , or a stereoisomer thereof, wherein R 3 and R 4 are independently hydrogen and C 1-6 alkyl.

12. The compound claim 1 , or a stereoisomer thereof, wherein R 1 and R 2 together are ═NR 5 .

13. The compound of claim 12 , or a stereoisomer thereof, wherein R 5 is —OCH 3 .

14. The compound of claim 1 , or a stereoisomer thereof, wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , or a stereoisomer thereof, wherein the compound is

16. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignees

• Univ Pennsylvania

Inventors

• Smith Iii Amos B
• An Chihui
• Hoye Adam T

Classifications

• C07D407/06 Primary

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title